Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats
rHuEPO plays a central role as chemicals for the treatment of many diseases. Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. After a single intramuscular administration of different doses o...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Analytical Methods in Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2014/918686 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548475578875904 |
|---|---|
| author | Xiaohan Cao Zhiyong Chen Zhuoran Yu Yonghong Ge Xianyin Zeng |
| author_facet | Xiaohan Cao Zhiyong Chen Zhuoran Yu Yonghong Ge Xianyin Zeng |
| author_sort | Xiaohan Cao |
| collection | DOAJ |
| description | rHuEPO plays a central role as chemicals for the treatment of many diseases. Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. After a single intramuscular administration of different doses of 125I-PEG-rHuEPO, pharmacokinetic parameters, tissue distribution, and excretion were analyzed. In in vivo half-life time measured after 125I-PEG-rHuEPO administration at the doses of 1, 2, and 3 μg/kg, t1/2α was 1.90, 1.19, and 2.50 hours, respectively, whereas t1/2β was 22.37, 26.21, and 20.92 hours, respectively; at 8, 24, and 48 hours after intramuscular administration, PEG-rHuEPO was distributed to all of the examined tissues, however, with high concentrations of radioactivity, only in plasma, blood, muscle at the administration site, and bone marrow. Following a 2 μg/kg single intramuscular administration, approximately 21% of the radiolabeled dose was recovered after almost seven days of study. Urine was the major route of excretion; 20% of the administered dose was recovered in the urine, while excretion in the feces was less than 1.4%. Therefore, this PEG-rHuEPO has potential to be clinically used and could reduce frequency of injection. |
| format | Article |
| id | doaj-art-8b2f415e2e2447c393c6c497a72936b0 |
| institution | Kabale University |
| issn | 2090-8865 2090-8873 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Analytical Methods in Chemistry |
| spelling | doaj-art-8b2f415e2e2447c393c6c497a72936b02025-02-03T06:13:57ZengWileyJournal of Analytical Methods in Chemistry2090-88652090-88732014-01-01201410.1155/2014/918686918686Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in RatsXiaohan Cao0Zhiyong Chen1Zhuoran Yu2Yonghong Ge3Xianyin Zeng4Isotope Research Laboratory, Sichuan Agricultural University, Ya’an 625014, ChinaChengdu Institute of Biological Products, Chengdu 610023, ChinaIsotope Research Laboratory, Sichuan Agricultural University, Ya’an 625014, ChinaChengdu Institute of Biological Products, Chengdu 610023, ChinaIsotope Research Laboratory, Sichuan Agricultural University, Ya’an 625014, ChinarHuEPO plays a central role as chemicals for the treatment of many diseases. Due to its short half-life, the main aim for this pharmacokinetic study is to investigate a newly developed PEG-rHuEPO with large molecular weight in SD rats. After a single intramuscular administration of different doses of 125I-PEG-rHuEPO, pharmacokinetic parameters, tissue distribution, and excretion were analyzed. In in vivo half-life time measured after 125I-PEG-rHuEPO administration at the doses of 1, 2, and 3 μg/kg, t1/2α was 1.90, 1.19, and 2.50 hours, respectively, whereas t1/2β was 22.37, 26.21, and 20.92 hours, respectively; at 8, 24, and 48 hours after intramuscular administration, PEG-rHuEPO was distributed to all of the examined tissues, however, with high concentrations of radioactivity, only in plasma, blood, muscle at the administration site, and bone marrow. Following a 2 μg/kg single intramuscular administration, approximately 21% of the radiolabeled dose was recovered after almost seven days of study. Urine was the major route of excretion; 20% of the administered dose was recovered in the urine, while excretion in the feces was less than 1.4%. Therefore, this PEG-rHuEPO has potential to be clinically used and could reduce frequency of injection.http://dx.doi.org/10.1155/2014/918686 |
| spellingShingle | Xiaohan Cao Zhiyong Chen Zhuoran Yu Yonghong Ge Xianyin Zeng Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats Journal of Analytical Methods in Chemistry |
| title | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| title_full | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| title_fullStr | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| title_full_unstemmed | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| title_short | Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats |
| title_sort | pharmacokinetics of pegylated recombinant human erythropoietin in rats |
| url | http://dx.doi.org/10.1155/2014/918686 |
| work_keys_str_mv | AT xiaohancao pharmacokineticsofpegylatedrecombinanthumanerythropoietininrats AT zhiyongchen pharmacokineticsofpegylatedrecombinanthumanerythropoietininrats AT zhuoranyu pharmacokineticsofpegylatedrecombinanthumanerythropoietininrats AT yonghongge pharmacokineticsofpegylatedrecombinanthumanerythropoietininrats AT xianyinzeng pharmacokineticsofpegylatedrecombinanthumanerythropoietininrats |